Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma

Phase 2

Active, not recruiting

Conditions: Metastatic Colorectal Adenocarcinoma

Interventions: Drug: Regorafenib

First Posted Date: 2013-12-30

Last Posted Date: 2024-01-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT02023333

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Queens Cancer Center of Queens Hospital, Jamaica, New York, United States

and more 4 locations

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

Not Applicable

Completed

Conditions: Esophagogastric Cancer

Interventions: Radiation: 89Zr-DFO-trastuzumab
Device: PET imaging

First Posted Date: 2013-12-30

Last Posted Date: 2024-12-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 42

Registration Number: NCT02023996

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Prognostic Awareness and Patient-Physician Communication in Malignant Glioma

Completed

Conditions: Malignant Glioma

Interventions: Behavioral: surveys and cognitive tests

First Posted Date: 2013-12-30

Last Posted Date: 2018-11-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 95

Registration Number: NCT02023346

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, New York, New York, United States

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

Phase 2

Active, not recruiting

Conditions: Metastatic Castration Sensitive Prostate Cancer

Interventions: Drug: Degarelix
Drug: Ipilimumab
Procedure: Radical Prostatectomy

First Posted Date: 2013-12-24

Last Posted Date: 2024-08-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 16

Registration Number: NCT02020070

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients

Not Applicable

Completed

Conditions: Non-Small-Cell-Lung Cancer (NSCLC)

Interventions: Drug: 18F-FMISO
Other: PET/CT

First Posted Date: 2013-12-20

Last Posted Date: 2024-07-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 29

Registration Number: NCT02016872

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

Phase 2

Active, not recruiting

Conditions: Rectal Cancer

Interventions: Drug: Oxaliplatin (OXAL)
Drug: 5-Fluorouracil (5-FU)
Drug: Leucovorin
Drug: Capecitabine (Xeloda®)
Radiation: intensity modulated radiotherapy (IMRT)
Behavioral: Quality of Life Questionnaires
Procedure: DRE-Endoscopy

First Posted Date: 2013-12-11

Last Posted Date: 2024-05-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 358

Registration Number: NCT02008656

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States
🇺🇸
University of Virginia, Charlottesville, Virginia, United States

and more 23 locations

CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Other: Standard of care
Biological: CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)

First Posted Date: 2013-11-26

Last Posted Date: 2024-02-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT01995708

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia (AML)
Myelodysplastic Syndromes (MDS)

Interventions: Drug: low dose 5'-azacitidine

First Posted Date: 2013-11-26

Last Posted Date: 2024-05-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 32

Registration Number: NCT01995578

Locations: 🇺🇸
Memorial Sloan Kettering Commack (Consent and Follow-up), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (Consent and Follow-up), Harrison, New York, United States

and more 4 locations

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Phase 1

Active, not recruiting

Conditions: Gastrointestinal Stromal Tumor (GIST)

Interventions: Drug: MEK162
Drug: Imatinib Mesylate (Gleevec®; STI571; NSC #716051)
Other: Blood draws
Procedure: biopsy

First Posted Date: 2013-11-25

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 75

Registration Number: NCT01991379

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Pre-test Assessment
Behavioral: Pre test Counseling
Other: Blood draw
Behavioral: Post-test counseling, and post-test assessment
Behavioral: Follow-up assessments (6 and 12 months)

First Posted Date: 2013-11-25

Last Posted Date: 2017-12-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 197

Registration Number: NCT01992471

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy